X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will support the preclinical development of BITT’s BITT-101, a novel dominant CD40 antagonist antibody for use in the treatment of Sjögren’s Syndrome.
Lead Product(s): BITT-101
Therapeutic Area: Immunology Product Name: BITT-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 31, 2023
Details:
BITT2101 is an investigational, novel, tumor necrosis factor superfamily receptor (TNFSR) antagonist antibody, which is being investigated for the treatment in patients with relapsed or refractory Non-Hodgkin’s lymphomas.
Lead Product(s): BITT2101
Therapeutic Area: Oncology Product Name: BITT2101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2023
Details:
BITT-CD4D11 and BITT-CD4F10, CD40 antagonists, are being developed for indications in autoimmunity and inflammation including Crohn’s disease, inflammatory bowel disease, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s syndrome.
Lead Product(s): BITT-CD4D11
Therapeutic Area: Gastroenterology Product Name: BITT-CD4D11
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
The agreement focuses to develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 (TNFR2) antagonist antibody for the treatment of cancers and infectious diseases.
Lead Product(s): BITR2101
Therapeutic Area: Oncology Product Name: BITR2101
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: KBI Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2021
Details:
BeiGene has secured an option to an exclusive license to develop, manufacture, and commercialize BITT’s TNFR2 antagonist antibodies in Asia (ex-Japan), Australia, and New Zealand. Parties plan to conduct Phase 1 trials of BITR2101 and combination studies with tislelizumab.
Lead Product(s): BITR2101,Tislelizumab
Therapeutic Area: Oncology Product Name: BITR2101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: $125.6 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
